<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04930328</url>
  </required_header>
  <id_info>
    <org_study_id>GBT440-4R1</org_study_id>
    <nct_id>NCT04930328</nct_id>
  </id_info>
  <brief_title>Retrospective Real World Oxbryta速 Data Collection and Analysis Study</brief_title>
  <acronym>RETRO</acronym>
  <official_title>A Retrospective Data Collection and Analysis Study of Patients With Sickle Cell Disease (SCD) Who Have Been Treated With Oxbryta速 (Voxelotor)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Blood Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Blood Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to collect and analyze retrospective data on Oxbryta in a real-world&#xD;
      setting. This is a multicenter, retrospective data collection and analysis study to&#xD;
      characterize health outcomes in approximately 300 patients with SCD who have been treated&#xD;
      with Oxbryta as part of their usual care. Any patient with SCD who received Oxbryta treatment&#xD;
      for at least 2 weeks as part of their usual care according to the Oxbryta US Prescribing&#xD;
      Information (USPI) is eligible to participate. Study data from 1 year before and up to 1 year&#xD;
      after the first dose of Oxbryta will be entered in case report forms (CRFs) via an electronic&#xD;
      data capture (EDC) system by the study staff.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following are categories of interest in patients with SCD treated with Oxbryta:&#xD;
&#xD;
        -  Clinical outcomes, as assessed by clinical and laboratory assessments of hematological&#xD;
           parameters and end organ damage, and incidence of significant clinical events&#xD;
&#xD;
        -  Healthcare resource utilization&#xD;
&#xD;
        -  Health-related quality of life (HRQoL), as assessed by patient-reported outcome (PRO)&#xD;
           measures and clinician-reported outcomes (ClinRO)&#xD;
&#xD;
      The safety objective is to assess the safety and tolerability of Oxbryta.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from pre-Oxbryta treatment period in Hemoglobin (Hb)</measure>
    <time_frame>1 year before and 1 year after the first dose of Oxbryta</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from pre-Oxbryta treatment period in percent Reticulocytes</measure>
    <time_frame>1 year before and 1 year after the first dose of Oxbryta</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from pre-Oxbryta treatment period in Absolute Reticulocytes</measure>
    <time_frame>1 year before and 1 year after the first dose of Oxbryta</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from pre-Oxbryta treatment period in Bilirubin</measure>
    <time_frame>1 year before and 1 year after the first dose of Oxbryta</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of significant SCD-related clinical events</measure>
    <time_frame>1 year before and 1 year after the first dose of Oxbryta</time_frame>
    <description>Such as vaso-occlusive crisis (VOC), acute chest syndrome (ACS), priapism, cerebral infarcts, transient ischemic attack (TIA), leg ulcers, and measures of cardiac function and pulmonary hypertension (PH)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from pre-Oxbryta treatment period in incidence of unplanned clinic visits</measure>
    <time_frame>1 year before and 1 year after the first dose of Oxbryta</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from pre-Oxbryta treatment period in incidence of emergency department (ED) visits</measure>
    <time_frame>1 year before and 1 year after the first dose of Oxbryta</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from pre-Oxbryta treatment period in incidence of hospitalizations (including total length of stay and time in intensive care unit [ICU], if applicable)</measure>
    <time_frame>1 year before and 1 year after the first dose of Oxbryta</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from pre-Oxbryta treatment period in incidence of red blood cell transfusions</measure>
    <time_frame>1 year before and 1 year after the first dose of Oxbryta</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of serious adverse events (SAEs)</measure>
    <time_frame>1 year before and 1 year after the first dose of Oxbryta</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of adverse events (AEs) of interest</measure>
    <time_frame>1 year before and 1 year after the first dose of Oxbryta</time_frame>
    <description>Such as Rash, Diarrhea, Headache, AEs leading to Oxbryta dose modification or discontinuation</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Retrospective Data Collection</arm_group_label>
    <description>Retrospective Data Collection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxbryta速 (voxelotor) 500-mg Tablets</intervention_name>
    <description>Patients will have received treatment with Oxbryta as prescribed by their physician at the approved dose per local prescribing information, as part of their usual care.</description>
    <arm_group_label>Retrospective Data Collection</arm_group_label>
    <other_name>Voxelotor</other_name>
    <other_name>Oxbryta速</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients at each participating study site who have been treated with Oxbryta will be&#xD;
        considered for inclusion in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients who meet all the following criteria will be eligible for inclusion in this study:&#xD;
&#xD;
          1. Willing and able to provide written informed consent (ages greater or equal to 18&#xD;
             years) or parental/guardian consent and patient assent (age &lt;18 years), as required by&#xD;
             the IRB or institution or IRB, per local regulations&#xD;
&#xD;
          2. Male or female patients with documented diagnosis of SCD (all genotypes)&#xD;
&#xD;
          3. Have been treated with Oxbryta for at least 2 weeks, according to the Oxbryta USPI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Purdie, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Global Blood Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Xu, MD</last_name>
    <phone>650-534-2574</phone>
    <email>mxu@gbt.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julia Martinisi, CAPM, PMP</last_name>
    <phone>650-452-7918</phone>
    <email>jmartinisi@gbt.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uconn Health</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030-1163</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franklin Ude</last_name>
      <phone>860-679-8822</phone>
      <email>Ude@uchc.edu</email>
    </contact>
    <investigator>
      <last_name>Biree Andemariam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Achebe, MD</last_name>
      <phone>617-732-5048</phone>
      <email>MACHEBE@BWH.HARVARD.EDU</email>
    </contact>
    <investigator>
      <last_name>Maureen Achebe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharada Sarnaik, MD</last_name>
      <phone>313-745-5515</phone>
      <email>ssarnaik@dmc.org</email>
    </contact>
    <investigator>
      <last_name>Sharada Sarnaik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey Rutgers Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yue Hao</last_name>
      <phone>732-235-8749</phone>
      <email>yh490@rwjms.rutgers.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Castro, MD</last_name>
      <phone>732-235-9637</phone>
      <email>elizabca@cinj.rutgers.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Drachtman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markenya Mirander</last_name>
      <phone>718-379-6863</phone>
      <email>MMIRANDE@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Susanna Curtis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atrium Health Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ifeyinwa Osunkwo, MD</last_name>
      <phone>980-442-2000</phone>
      <email>ify.osunkwo@atriumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Ifeyinwa Osunkwo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Padrick</last_name>
      <phone>919-684-2406</phone>
      <email>stephanie.padrick@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Nirmish Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridgette Larkin-Perkin</last_name>
      <phone>214-648-7507</phone>
      <email>Bridgette.Larkin-Perkins@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Alecia Nero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelica Rodriguez</last_name>
      <phone>713-500-6544</phone>
      <email>angelica.r.rodriguez@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Modupe Idowu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 4, 2021</study_first_submitted>
  <study_first_submitted_qc>June 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sickle Cell Disease Registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

